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Dear Editor, 
Amyloidosis is characterized by deposition of specific amyloid proteins in the tissues. 
Since different amyloid proteins have similar fibrillar structures, aggregation of distinct 
amyloid proteins may exhibit cross-seeding effects on each other, resulting in fibril 
formation of different amyloid proteins, as observed in experimental models and patients 
[1–4]. Transthyretin (TTR) is a common cause of systemic amyloidosis affecting heart, 
peripheral and autonomic nervous system, and eye. Moreover, cerebral amyloid 
angiopathy (CAA) was demonstrated in some patients with systemic TTR amyloidosis 
with mutations in the TTR gene [5]. CAA frequently occurs in the long-term clinical 
course after liver transplantation [6]. Here, we describe an autopsy case of late-onset 
systemic TTR amyloidosis with a V30M mutation in TTR showing severe CAA. 
Interestingly, TTR as well as amyloid β protein (Aβ) were deposited in the cerebral 
leptomeningeal and cortical blood vessel walls. Most of the TTR and Aβ amyloid 
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deposited independently on the vessel walls; however, a part of the vessel wall was 
occupied by a combination of TTR and Aβ. This case provides novel insights into the 
interaction of amyloidogenic proteins in humans.  
An 84-year-old man with unremarkable family history developed lower and 
upper limb weakness, constipation, and anhydrosis at the age of 73. Dysesthesia of the 
extremities appeared later. His symptoms gradually deteriorated. At the age of 77, he 
received a diagnosis of hereditary systemic TTR amyloidosis with TTR V30M mutation 
based on TTR-positive amyloid deposition in the sural nerve and genetic analysis. Oral 
administration of diflunisal was started [7]; however, his symptoms related to neuropathy 
and cardiac dysfunction deteriorated. Autonomic dysfunction gradually emerged. 
Diflunisal was replaced with tafamidis at the age of 83. The patient presented disturbance 
of immediate memory followed by dementia with hallucination one year before the death. 
During the course of the disease, he did not show episodes of transient neurological 
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symptoms due to central nervous system dysfunction (amyloid spells). He died of heart 
failure due to amyloidosis at the age of 84. The total clinical course was 11 years.  
Paraffin specimens of the tissues fixed with 10% buffered formalin were 
examined. Selected sections were immunostained using the ABC method with a 
Vectastain ABC kit (Vector, CA, USA). Double immunofluorescence was also performed 
(Fig. 1).  
A general autopsy was performed 8.5 hours after the death. Systemic amyloid 
deposition was evident in the visceral organs. The brain and dura mater showed mild 
dilatation of the lateral ventricles and weighed 1,355 g before fixation. Macroscopic 
examinations revealed mild depigmentation in the substantia nigra and locus ceruleus. 
Microscopically, severe loss of myelinated fibers with TTR-positive amyloid deposition 
was demonstrated in the peripheral nerves. The dorsal root ganglia, sympathetic ganglia, 
skin, and pituitary also demonstrated considerable TTR-positive amyloid deposition (Fig. 
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1a). In addition to TTR-positive amyloid deposition in the dura mater, leptomeninges, 
subpial areas (Fig. 1b), and leptomeningeal blood vessels throughout the central nervous 
system, the cerebral cortical blood vessels showed CAA (Fig. 1c) comprising extensive 
TTR-positive amyloid deposition (Figs. 1b, d, g); however, no TTR-positive amyloid 
structures were observed in the brain and spinal cord parenchyma. Furthermore, 
widespread Aβ-positive senile plaques were observed (CERAD B; Braak stage B [8]; 
Thal phase 2). The cerebral cortical and leptomeningeal CAA (Fig. 1c) also consisted of 
Aβ (Figs. 1e, h). Circumferential positivity for Aβ was observed in some but not all 
leptomeningeal or cortical blood vessels in the cerebral cortices. Aβ deposition in the 
vessels walls was more apparent in the occipital lobe. No Aβ-type CAA was observed in 
the cerebellum, brainstem, or spinal cord. Interestingly, most of the TTR and Aβ 
deposited independently on the vessel walls, as analyzed using the double labeling 
method. A part of vessel wall was occupied by a combination of TTR and Aβ (Figs. 1f, i). 
                             Sakai et al. -6- 
Regarding CAA-associated neuropathological findings, no obvious hemorrhages, 
microinfarcts, or white matter damages were revealed. Although tau pathology was 
confined to the medial temporal lobe (Braak & Braak stage I; Braak AT8 stage II) [8], 
Lewy body pathology was observed in the limbic systems and brainstem (Limbic stage) 
[9].  
In systemic TTR amyloidosis with specific mutations, mutant TTR proteins 
produced by the choroid plexus may deposit in the leptomeningeal and cortical blood 
vessel walls as in TTR-type CAA [5, 6]. Regardless of liver transplantation, central 
nervous system clinical symptoms frequently occurred in patients with systemic TTR 
amyloidosis with a V30M mutation in the TTR gene [6]. Interestingly, coexistence of 
TTR- and Aβ-type CAA in a single case, as found in this patient, has never been reported 
so far. Since our patient demonstrated manifestations regarding TTR amyloidosis at the 
age of 73, this case also developed Aβ-type CAA, which is commonly observed in elder 
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people. Aβ-type CAA has been considered to be consequence of a failure of intramural 
periarterial drainage owing to modification of the cerebrovascular basement membrane 
[10]. Although TTR deposition in the vessel walls could damage this perivascular 
drainage pathway, it is unlikely that widespread occurrence of vascular TTR deposition 
exerted an influence on development of Aβ-type CAA in this case due to the fact that 
distribution of Aβ-type CAA was an ordinary manner, such as a predominance in the 
occipital lobe.  
Regarding cause of dementia in our patient observed one year before the death, 
Lewy body pathology could make a profound impact on the dementia the result of less 
severity of the tau pathology [9]. Meanwhile, moderate-to-very severe Aβ-type 
neocortical CAA is associated with decreased perceptual speed after adjusting for 
comorbid parenchymal Alzheimer’s disease pathology and Lewy body pathology [11]. 
Moreover, several specific TTR gene mutations present central nervous system 
                             Sakai et al. -8- 
manifestations including dementia [12]. Although assessments of the cognitive 
dysfunction in our patient were inadequate, severe CAA observed in this case, which is 
comprised of TTR- and Aβ-type, might be related to development of dementia.  
Several in vivo [1, 3, 4] and in vitro [2] evidence suggest cross-seeding effects 
of amyloidogenic proteins. Amylin and Aβ show cross-seeding effects and may deposit 
as a combination of amyloid in the human brain parenchyma and blood vessels [1, 3]. 
Apolipoprotein AI (ApoAI) and TTR co-localized in amyloid deposits of the biopsied 
tissues in a patient with apoAI amyloidosis with Leu78His mutation [4]. Moreover, 
hybrid amyloid fibril comprising Aβ and amylin has been previously generated in vitro 
[2]. Our findings, however, that most of the TTR and Aβ in the vessel walls deposited 
independently (Figs. 1f, i) indicate that cross-seeding of TTR and Aβ is less likely in 
humans. TTR, a protein in the cerebrospinal fluid, was reported to bind to Aβ and inhibit 
Aβ aggregation in vitro [13]. An in vivo experiment using human kidney also revealed 
                             Sakai et al. -9- 
that TTR plays an important role in the sequestration of Aβ to prevent Aβ aggregation and 
amyloid formation in the kidney [14]. On the other hand, a study using Alzheimer’s 
disease mice model demonstrated that TTR is associated with increase of Aβ deposition 
on the vessel walls [15]. Due to the fact that experimental and in vivo human evidence of 
association between TTR and Aβ is inconsistent, further studies are essential to clarify 
interaction between TTR and Aβ in the human brain.  
In conclusion, we describe an autopsy case of late-onset systemic TTR 
amyloidosis with a V30M mutation in TTR showing coexistence of TTR- and Aβ-type 
CAA in the central nervous system. Independent deposition of the TTR and Aβ amyloid 
on the vessel walls provides novel insights into the interaction of amyloidogenic proteins, 
including TTR and Aβ, in humans. This case raises the need for specific amyloid tracers 
for in vivo diagnosis. 
(1,249 words) 
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Figure legend 
Figure 1 Postmortem neuropathological findings.  
(a) The dorsal root ganglion shows widespread Congo red-positive amyloid deposition. 
(b) Amyloid deposits immunolabeled for transthyretin (TTR) are observed around the 
lumbar spinal cord and leptomeningeal blood vessels.  
(c) Congo red-positive amyloid deposition (cerebral amyloid angiopathy, CAA) is 
observed in the leptomeningeal and cerebral cortical blood vessels.  
(d-f) Serial sections demonstrate that CAA comprises both TTR (d) and amyloid β protein 
(Aβ) (e) deposition. Most of the TTR and Aβ deposits are separately distributed in the 
vessel walls (f).  
(g-i) In another leptomeningeal blood vessel, a part of the vessel wall is occupied by 
combination of TTR and Aβ amyloid (arrow).  
The primary antibodies used are as follows: Aβ (4G8; mouse monoclonal; Covance; 
1:5000) and prealbumin (TTR) (rabbit monoclonal; Abcam; 1:100). Double 
immunofluorescence is performed using primary antibodies to Aβ (4G8; 1:500), 
prealbumin (1:50), and secondary antibodies conjugated with Alexa 488 (Invitrogen, 
1:400, green) or Alexa 568 (1:400, red) fluorochromes, respectively.  
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Congo red (a, c); immunostaining for TTR (b, d, g), and Aβ (e, h). Merged images of TTR 
and Aβ (f, i).  Scale Bars = 200 μm (a); 1 mm (b); 100 µm (c-i). 

